cyrilzakka/clinical-trials huggingface dataset:
SERS-Based Serum Molecular Spectral Screening for Lung Cancer Type

Lung cancer can be divided into two major categories: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), with NSCLC accounting for about 85% and SCLC about 15%. The prognoses of different types of lung cancer vary significantly. Early identification of different pathological types of lung cancer is crucial to the patient's prognosis.

Raman Spectrum (RS), as a non-invasive and highly specific molecular detection technique, can obtain information at the molecular level, thereby sensitively detecting changes in biomolecules related to tumor metabolism such as proteins, nucleic acids, lipids, and sugars. Surface-enhanced Raman spectroscopy (SERS), developed based on this technology, is one of the feasible methods for high-sensitivity biomolecular analysis.

In preliminary study, the investigators collected serum Raman spectral data from a cohort of 233 patients with malignant lung tumors and built a Raman intelligent diagnostic system for SCLC and NSCLC based on a machine learning model, achieving an accuracy rate of 80%. To obtain the highest level of clinical evidence and truly achieve clinical translation, this prospective, multicenter clinical study aims to validate the use of this intelligent diagnostic system for the early diagnosis of SCLC.

1. Screening interested participants should sign the appropriate informed consent (ICF) prior to completion any study procedures.
2. The investigator will review symptoms, risk factors, and other non-invasive inclusion and exclusion criteria.
3. Completion of baseline procedures, participants were assessed for 30 days and completed all safety monitoring.
4. After completing the baseline assessment and confirming enrollment, participants will be given 2ml of fasting venous blood.

Eligibility Criteria:
Inclusion Criteria:

1. Participants with Lung cancer meeting the criteria of TNM (Ninth Edition);
2. Participants are willing to participate in this study and follow the research plan;
3. Participants or legally authorized representatives can give written informed consent approved by the Ethics Review Committee that manages the website;.

Exclusion Criteria:

1. Participants with concomitant other malignant tumors;
2. Participants with missing baseline clinical data;
3. Participants with severe underlying pulmonary diseases (such as bronchiectasis, bronchial asthma, or COPD), or those with a history of occupational or environmental exposure to dust, mines, or asbestos;
4. Participants who are uncooperative or refuse to participate in the clinical trial later on.
Effects of Motor and Sensory Exercises on Hand Functions

This project will compare the effectiveness of sensory and motor exercises used in clinical settings for healthy young adults. This approach will allow the investigators to evaluate the impact of these exercises on hand functions.

The study plans to include 60 healthy young adults aged 18-25. After providing participants with information about the study's purpose, written informed consent will be obtained to confirm voluntary participation. Participants will be randomly assigned to one of three groups: "sensory exercise," "motor exercise," and "sensory and motor exercise." The effects on muscle reaction time and hand skills for the dominant and non-dominant hands will be evaluated before and after the exercises.

Hand functions occupy a significant place in the functional activities of daily life. Therefore, impairments in wrist function can severely impact daily activities and quality of life. Hand rehabilitation includes various methods aimed at improving hand functions for treating numerous conditions affecting the wrist. However, it has been determined that treatments targeting both motor and sensory functions should be used together to enhance functionality. For this purpose, this project will compare the effectiveness of sensory and motor exercises used in clinical settings in healthy young adults, allowing investigators to evaluate their impact on hand functions.

The study will include 60 healthy young adults aged 18-25. After participants are informed about the study's purpose, written informed consent will be obtained to confirm voluntary participation. Participants will be randomly assigned to one of three groups: "sensory exercise," "motor exercise," and "sensory and motor exercise." The effects on muscle reaction time and hand skills for the dominant and non-dominant hands will be evaluated before and after the exercises. Data from the study will be analyzed using the Statistical Package for the Social Sciences (SPSS) version 25.0. Demographic characteristics of participants will be expressed as arithmetic mean ± standard deviation and percentages. The normal distribution of data will be examined using visual (histogram and probability plots) and analytical methods (Kolmogorov-Smirnov/Shapiro-Wilk tests). Pre- and post-evaluations within groups will be assessed using the student-t test, and intergroup comparisons will be evaluated with the student-t test if data follows a normal distribution, or with the Mann-Whitney U test if not. A p-value of \<0.05 will be considered statistically significant.

Eligibility Criteria:
Inclusion Criteria:

* Having the ability to verbally communicate to answer questions
* Willingness to participate in the study
* Having read and signed the informed consent form

Exclusion Criteria:

* Having joint movement restriction in the upper extremity
* Presence of skin injury or scarring on the hand or wrist
* History of surgery on the upper extremity
* Having an orthopedic problem in the upper extremity
* Having a rheumatic disease
* Having a neurological condition in the upper extremity
* Having a severe mental or cognitive impairment
Comparison Study of Breast Computed Tomography (CT) With Magnetic Resonance Imaging (MRI)

Lay Summary

After patients are diagnosed with breast cancer, they undergo breast magnetic resonance (MR) imaging to determine if the cancer is located in more than one place in the breast. Breast MR imaging is a good option for this test because it has very high sensitivity (catches almost all breast tumors). However, breast MR is slow: it takes about two minutes to acquire one image, and is very low resolution. The points that make up the breast MR image are around 1 to 3 mm in size.

Dedicated breast computed tomography (or breast CT), a new way of imaging the breast, has been introduced in the last few years. Breast CT is an x-ray exam that uses 3D imaging to show the breast in its real three dimensional shape. Combined with the use of special chemicals called iodine contrast enhancement, breast CT can provide images of both the anatomy and the blood flow in the breast. As opposed to breast MR, breast CT is very fast. An image can be taken in 10 seconds, and has very high resolution. The points in the breast CT image are only 0.14 mm in size. The investigators propose to use breast CT instead of breast MR imaging to determine if the patient's breast cancer is located in more than one place. This is the first time anybody has proposed to use breast CT for this, so the investigators aim to test the feasibility of the idea with only 6 patients.

Since the patients will undergo breast MR as part of the standard of care, the investigators will be able to compare the breast CT images to the current standard, breast MR. This work will lay a foundation for performing this very important test before breast cancer treatment planning with a new, fast, high resolution imaging method, breast CT.

See above

Eligibility Criteria:
3.1 Eligibility Criteria All subjects will be women at least 35 years of age that have been diagnosed with breast cancer and have undergone breast MR imaging for detection of multifocal/multicentric disease.

3.2 Ineligibility Criteria

* Subject does not meet any of the inclusion criteria
* Women with suspected or confirmed pregnancy
* Women who have had bilateral mastectomy
* Women who are very frail and unable to cooperate
* Women who cannot give informed consent
* Male subjects
* Women with implants
Electronic Cigarettes as a Harm Reduction Strategy in Individuals With Substance Use Disorder

Patients in addiction treatment have exceptionally higher rate of cigarette smoking and very low quit rates compared to the general population. The purpose of this study is to examine the feasibility of using e-cigarettes as a method for harm reduction and the effects of providing e-cigarettes (or placebo e-cigarettes) on smoking outcomes among patients in addiction treatment.

Electronic nicotine delivery devices often referred to as e-cigarettes, are battery-powered devices that deliver vaporized nicotine when inhaled. Corresponding with the growth in media attention, marketing and promotion, awareness and use of e-cigarettes has increased dramatically. A large proportion of those using e-cigarettes use them to reduce the number of cigarettes they are smoking or to help them quit. Use of an e-cigarette by smokers unwilling or unable to stop smoking completely might be a good approach to reducing cigarette consumption as the e-cigarette imitates some behavioral aspects of cigarette smoking and contains nicotine. Moreover, the few existing studies on the effect of e-cigarettes on tobacco withdrawal and craving suggest promising potential to assist smokers in coping with smoking urges and decreasing cigarette use.

Eligibility Criteria:
Inclusion Criteria:

* smokes at least 10 cigarettes per day
* meet DSM-V AUD and/or OUD within the past year, interested in reducing CPDs
* able to provide consent
* use a cell phone, are willing/able to receive and respond to daily text messages regarding their cigarette use and e-cigarette use on their cell phone
* provide one additional contact, and are willing to use an e-cigarette for 3 weeks.

Exclusion Criteria:

* pregnant and/or breast feeding (self-reported)
* currently using smoking cessation medications (including other forms of NRT, buproprion, or varenicline)
* enrolled in a smoking cessation program or another cessation tria
* have used an e-cigarette in the past 14 days
* have used any other tobacco products (pipe, cigar, cigarillos, snuff, chewing tobacco, rolling tobacco, or hookah/shisha) in the past 30 days
* report having a history of asthma, other airways diseases, or heart disease.
Algorithms to Diagnose Pulmonary Arterial Hypertension

The investigators intend to evalute the value of radiomics signature of pulmonary vessels from chest computed tomography (CT) for dianosis and prognosis of pulmonary arterial hypertension.

Pulmonary arterial hypertension (PAH) is a heterogeneous disorder composed of varying pathobiology that may involve multiple clinical conditions. Computed tomography (CT) is a minimally invasive imaging technique capable of providing both high contrast and high resolution detail of the lungs and arteries. Application of radiomics as prognosis and diagnosis tools could quantifies high-dimensional features from CT data to investigate vescualr heterogeneity.Development and validation of PAH diagnosis Algorithms based on radiomics may serve as a complementary readout to current CT-based metrics and provide valuable evidence to make the treatment management decision in early PAH.

Eligibility Criteria:
Inclusion Criteria:

1. Chest CT examination and cardiac ultrasound examination were performed within 3 months before and after right heart catheterization;
2. mPAP \> 25mmHg and PVR\< 3woods (measured by right heart catheter) and pulmonary vascular resistance was collected as PAH group whereas Healthy Volunteers as non-PAH control group in developement corhort;
3. sPAP \> 36mmHg (measured by echocardiography) was collected in validation corhort.

Exclusion Criteria:

1.Cancer; 2. The quality of chest CT and cardiac ultrasound images is poor; 3.Pulmonary vascular segmentation is affected by thoracic organ displacement or pulmonary vascular complete occlusion due to diseases ,such as spinal deformity.
Exercise Induced Bronchospasm in Children

The purpose of the study is to test how well 2 different medications stop asthma symptoms caused by exercising. The two medications that will be tested are "pretreatment with albuterol" and montelukast (Singulair®). Although both medications are used for treating asthma, we don't know which medicine is better at stopping asthma symptoms caused by exercising.

TThis is a randomized, crossover, placebo controlled trial of 30 patients, 7-17 years old with confirmed EIB. Patients will be randomized to montelukast treatment for at least 3 days or pretreatment with albuterol before an exercise challenge. Villiran and colleagues have shown that the protective effect of montelukast in treating EIB is apparent at day 3 of treatment and comparable to treatment for 4 and 8 weeks.

It is our hypothesis that pretreatment with albuterol will provide superior protection against breakthrough EIB in children with mild asthma compared to montelukast as maintenance therapy added to the current asthma regimen. Secondary aims of this study are to measure the effect of montelukast on leukotriene B4 (LTB4) concentrations as measured in EBC, and on inflammation measured by FeNO level. We hypothesize that since montelukast is a cysteinyl leukotriene receptor antagonist, patients with elevated concentration of LTB4 may have a greater response to this medication. Lastly, patients with elevated FeNO, a measure of airway inflammation respond differently to albuterol than montelukast his study is a randomized, double-blind, double-dummy, crossover clinical trial which will consist of 4 study visits and last up to 3 weeks.

Thirty children 7-17 years of age with asthma and EIB, regardless of current asthma therapy will be eligible for this trial. Patients will receive 3-7 days of therapy with either montelukast (5mg or 10 mg capsule) or placebo tablets. After 3-7 days of therapy the patients will be crossed over to receive the alternative therapy. Exercise challenges will be completed at screening, baseline, visit 3 and visit 4. All patients will have an albuterol metered-dose inhaler (MDI) to be used on an as needed basis for asthma symptoms.

Eligibility Criteria:
Inclusion Criteria:

* Children 7-17 years of age
* Physician diagnosed asthma for at least 6 months
* EIB diagnosed by a positive exercise challenge at screening and baseline visits
* Forced expiratory volume in 1 second (FEV1) ≥ 70% of predicted at screening and baseline visit

Exclusion Criteria:

* History of cardiac dysfunction
* Unable to perform exercise challenge
* Use of montelukast
DOSC and Association With Neighborhood Opportunity: Phase II

Prospective, qualitative interview study to explore factors associated with pediatric day of surgery cancellations (DOSC) from the prospective of parents with hopes the interviews will reveal additional vulnerabilities not included in COI 2.0 that predispose to DOSC.

We plan to prospectively study vulnerability factors that contribute to day of surgery cancellations (DOSC) by conducting a qualitative study using semi-structured interviews with families cancelled the day of surgery. We plan to enroll between 20-30 families using convenience sampling. Based on preliminary data, we anticipate that most families will come from minority racial and ethnic groups and parents of non-English primary language (NEPL) - these interviews will be conducted via an interpreter. Interviews will be structured to explore surgical care utilization themes based on the Gelberg-Anderson Behavioral Model for Vulnerable Populations including 1) Parental knowledge and attitudes regarding surgical services, 2) family and community resources, 3) Perceived surgical conditions and perceived need for surgical services, and 4) use of surgical services and difficulties accessing them. Family recruitment will be ongoing and will continue until we have reached saturation of themes. The data generated from this study will lay the foundation for a multi-layered intervention at the hospital level to allow patients to be triaged according to COI 2.0, race/ethnicity, NEPL status, and other vulnerabilities. This will enable adaptation of hospital pre-operative procedures (i.e. NPO preoperative calls) to reduce DOSC.

Eligibility Criteria:
Inclusion Criteria:

* Parents/guardians of children \<18 who had a day of surgery cancellation
* Parents/guardians speak English, Spanish, Somali, Nepali or Arabic.

Exclusion Criteria:

* Parents/guardians speak a different language other than above listed.
Study of Immune Response in Adults and Elderly Subjects Vaccinated With Inactivated Influenza Vaccines

To further characterize the immune responses induced after an influenza vaccination performed either via the ID or the IM routes in two clearly distinct populations.

Objectives:

* To describe the immune response per age group and vaccine group after vaccination.
* To describe the safety of the vaccines per age group and per vaccine group after vaccination.


Eligibility Criteria:
Inclusion Criteria :

* Aged 18 to 40 years (adults) or 60 to 85 years (elderly)
* Provision of a signed informed consent
* Able to attend all scheduled visits and comply with all trial procedures
* For a woman of child-bearing potential, avoid becoming pregnant (use of an effective method of contraception or abstinence) for at least 4 weeks prior to vaccination, until 4 weeks after vaccination
* Entitlement to national social security.

Exclusion Criteria :

* For a woman of child-bearing potential, known pregnancy or positive urine pregnancy test
* Breast-feeding woman
* Participation in another clinical trial investigating a vaccine, drug, medical device or a medical procedure in the 4 weeks preceding the trial vaccination
* Planned participation in another clinical trial during the present trial period
* Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy
* Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or to a vaccine containing any of the same substances
* Chronic illness, at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator
* Current alcohol abuse or drug addiction, which may interfere with the subject's ability to comply with trial procedures
* Receipt of blood or blood-derived products in the past 3 months, which might interfere with the assessment of immune response
* Receipt of any vaccine in the 4 weeks preceding the trial vaccination
* Planned receipt of any vaccine in the 4 weeks following the trial vaccination
* Known Human Immunodeficiency Virus, Hepatitis B or Hepatitis C seropositivity
* Previous vaccination against Influenza in the previous 6 months
* Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding the inclusion contraindicating IM vaccination
* Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent
* Febrile illness (oral temperature \>=37.5°C) or moderate or severe acute illness/infection on the day of vaccination, according to investigator judgment
Subjective Perception of Motor Control During Psychogenic Disorders

The aim of this study is to reveal neurobiological bases of the motor control of conscious perception, thanks to new techniques of functional cerebral imaging (MRI), and potentials deteriorations connected to neuropsychiatric disorders like conversion disorder.

The Hospital University Center of Grenoble will provide patients from Neurology department, characterized with non psychogenic epileptic seizures and abnormal psychogenic movements, from conversive origin.

Subjects will be scanned by Magnetic Resonance Imaging during a motor paradigm inducing a perceptive conflict between two informations : proprioceptive information coming from the action (drawing) and visual information (draw's mark) that appears on the screen when there is movement.

New results will be provided about brain mechanisms involved in motor control perception among healthy patients and patients suffering from functional neurologic symptoms.

Eligibility Criteria:
Inclusion Criteria:

* Signed informed consent
* Medical exam médical done before study participation
* Between 18 and 65 years
* Right-handed persons
* Conversion disorder based on DSM IV-R criterias
* Symptom affecting motor system, like abnormal movements (shivers, dystonia, parkinsonism, or problem when walking)

Exclusion Criteria:

* Subjects included in a clinical and/or therapeutic exeprimentation in progress
* People with MRI contraindications : prosthesis or metal implants, metallic teeth (dental) brace, pacemaker, IUD, possibility of pregnancy, claustrophobia
* Traitement médicamenteux psychotrope ou susceptible d'interférer avec le débit sanguin cérébral ou l'activité neuronale
* History of brain or disseminated and extendible lesions of white matter, of an other degenerative morbidity, a confusion or an insanity as well as serious deficits preventing language understanding.
* Alcohol ingestion
* Pregnant, parturient or breastfeeding women
* All other categories of protected persons